To characterize structural changes of HCQ retinopathy with SD-OCT after drug cessation. Setting: Private practice and academic institution. Patient Population: Patients at New England Eye Center and Ophthalmic Consultants of Boston in Boston, MA diagnosed with HCQ retinopathy and followed after drug cessation. Plaquenil peak Adverse effects of hydroxychloroquine Plaquenil for amyopathic dermatomyositis Hydroxychloroquine & methotrexate This article is from June 2011 and may contain outdated material. Download PDF. Many systemic medications may cause retinal toxicity. One such commonly used medication for dermatologic and rheumatologic inflammatory conditions is hydroxychloroquine Plaquenil, a chloroquine derivative. SD-OCT is capable of detecting characteristic macular changes of HCQ toxicity. These typical macular abnormalities include loss of the parafoveal ellipsoid zone EZ, parafoveal thinning of the outer nuclear layer ONL and inner plexiform layer IPL, the “flying saucer” sign, and peripapillary nerve fiber layer thinning 12 – 14. Of course the aim is avoid drug related retinal toxicity, which on ophthalmic examination, appears as the classic Bull’s eye change affecting the macula. Once retinal toxicity from hydroxychloroquine occurs, it is thought that the retinal changes are permanent and the disease can progress even if hydroxychloroquine is stopped for 1 to 3 years. Main Outcome Measures: SD-OCT findings suggestive of HCQ retinopathy before parafoveal ellipsoid disruption. Retrospective clinical data review by the Boston Image Reading Center. Plaquenil macular toxicity oct Protecting your eyesight when taking Plaquenil Lupus., Expanded spectral domain-OCT findings in the early. Do you have to wean off hydroxychloroquineHydroxychloroquine sulphate usesHydroxychloroquine dosage for osteoarthritisCan a blood test show if im taking plaquenil Many systemic medications may cause retinal toxicity. One such commonly used medication for dermatologic and rheumatologic inflammatory conditions is hydroxychloroquine Plaquenil, a chloroquine derivative. It is used to treat many diseases including malaria, rheumatoid arthritis and systemic lupus erythematosus. Hydroxychloroquine-Induced Retinal Toxicity - American.. My Take on New Ocular Screening Guidelines for Plaquenil.. How to Succeed in Plaquenil Screenings. Lyons emphasizes the importance of annual screening and says that, although annual screening is recommended for everyone taking Plaquenil, it is imperative for people who have been taking the medication for more than 10 years, who have a higher incidence of retinal toxicity. Plaquenil-induced toxicity usually will not occur before five years of. It is crucial to detect retinal toxicity induced by HCQ early and take necessary actions before it results in permanent visual loss. In our study, we demonstrated HCQ-induced retinal toxicity at an earlier stage through the measurement of RGC-IPL thickness by using SD-OCT, which is an easy-to-use and non- invasive method. SD-OCT showed loss of the parafoveal inner/outer segment junction, thinning of the parafoveal outer nuclear layer, and a loss of the normal foveal depression, which is characteristic for hydroxychloroquine retinal toxicity Figure 3.